HERZLIYA, Israel, and CALGARY, AB — Innocan Pharma Corporation, a pharmaceutical technology company focusing on developing drug delivery platform technologies, reported its financial consolidated results for the six months ended June 30, 2025.
First Half Of 2025 Financial Highlights
Revenues decreased 4% in the first half of 2025 to US$14.8M, compared to US$15.4M in the first half of 2024. The revenue decline was attributed to the uncertainty and volatility of the markets as a result of global trade tariffs.
Gross Profit decreased 4.9% in the first half of 2025 to US$13.3M compared to US$14.M in the first half of 2024.
Operating Profit increased by 130% to US$0.885M in the first half of 2025, compared to operating loss of US$0.680M in the first half of 2024.
“We are progressing towards the next important milestone following the public filing of Registration Statement for our proposed U.S. public offering, and Innocan has applied to list its Common Shares and Warrants on the Nasdaq Capital Market under the symbols “INNP” and “INNPW”, respectively,” CEO Iris Bincovich said.
About Innocan
Innocan is a pharmaceutical company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of self-care products. Under this segment, Innocan is a 40% shareholder in the joint venture company, BI Sky Global Ltd., which company focuses on targeted online sales.
Related Articles:
